Athera completes multiple dosing trial with its fully human antibody PC-mAb
Athera Biotechnologies AB today announced that last dosing in a multiple dosing study in healthy volunteers has been given with its fully human antibody PC-mAb, with continued support for development based on preliminary safety and pharmacokinetics reporting.
“We are very pleased with the progress of this MAD study and that the preliminary data support our plans with once monthly administration over longer time. We are looking forward to the complete results after the follow-up visits” says Carina Schmidt, CEO of Athera. “The study is a preparation for the Phase 2a study that we are planning to submit in the next month.”
The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: firstname.lastname@example.org
Läs mer på MyNewsDesk